Bio-Techne Executive and Leadership Team

James Hippel, the Executive Vice President & Chief Financial Officer at Bio-Techne, manages the global financial strategy and capital structure of the organization. Overseeing investor relations and financial reporting, the Executive Vice President & Chief Financial Officer ensures transparency and long-term value creation for stakeholders. This role involves analyzing market trends to guide investment in new bioactive reagent technologies. By maintaining a strong balance sheet, James Hippel supports the company's mission to provide accurate clinical diagnostic tools. The Executive Vice President & Chief Financial Officer collaborates with the board to execute mergers and acquisitions that expand the firm's research capabilities. Through disciplined financial planning, the executive drives the fiscal health required for continuous drug discovery efforts. This leadership position remains central to the company's ability to scale operations and maintain a dominant market position within the life sciences sector, ensuring consistent growth and operational stability.

Will Geist, the President, Protein Sciences Segment at Bio-Techne, oversees the strategic direction and commercial performance of the protein research division. Managing the development of specialized reagents, the President, Protein Sciences Segment ensures that the product portfolio meets the evolving needs of the global research community. This role involves driving market expansion for protein-based diagnostic tools. By coordinating with sales and marketing teams, Will Geist increases the adoption of these critical research assets. The President, Protein Sciences Segment monitors the competitive landscape to identify new opportunities for growth in drug discovery applications. Through the optimization of supply chains and production capabilities, the executive ensures the reliable delivery of high-quality biological tools. This leadership position supports the company's mission by providing the essential means for accurate clinical tests, ultimately contributing to a deeper understanding of disease mechanisms and the development of effective therapeutic interventions.

Laurie Gilman, the Vice President, Finance Operations & Chief of Staff at Bio-Techne, directs the integration of financial workflows with corporate administrative priorities. Managing complex operational budgets, the Vice President, Finance Operations & Chief of Staff ensures fiscal discipline across all research and diagnostic divisions. This role involves streamlining internal processes to support the global life sciences mission. By optimizing resource allocation, Laurie Gilman strengthens the financial foundation necessary for sustained innovation in bioactive reagents. The Vice President, Finance Operations & Chief of Staff coordinates closely with executive leadership to align departmental output with long-term growth objectives. Through rigorous oversight of financial operations, the executive maintains high standards of efficiency. This leadership position drives the operational agility required to navigate the competitive landscape of clinical diagnostics, ensuring that every financial decision supports the broader goal of advancing scientific investigations into biological processes.

Cheryl Bethune, the Senior Vice President & Chief Human Resources Officer at Bio-Techne, architects the talent acquisition and organizational development strategies essential for a global life sciences enterprise. Overseeing human capital initiatives, the Senior Vice President & Chief Human Resources Officer fosters a culture of scientific innovation and operational excellence. This role involves designing comprehensive programs to attract top-tier researchers and diagnostic experts. By implementing robust performance management systems, Cheryl Bethune ensures that the workforce remains aligned with the company's drug discovery goals. The Senior Vice President & Chief Human Resources Officer manages large-scale organizational changes to support expansion across international markets. Through strategic workforce planning, the executive secures the human resources needed to maintain a competitive edge in the research community. This leadership function directly impacts the ability of the organization to deliver high-quality tools for understanding disease progression and biological complexity.

Gary Latham, the Vice President & Chief Technology Officer at Bio-Techne, directs the research and development of innovative tools for the clinical diagnostic and life sciences communities. Overseeing the technical roadmap, the Vice President & Chief Technology Officer ensures the development of cutting-edge bioactive reagents that assist in complex biological investigations. This role involves bridging the gap between scientific discovery and commercial product application. By leading cross-functional engineering teams, Gary Latham accelerates the pace of drug discovery efforts. The Vice President & Chief Technology Officer monitors emerging technologies to maintain the company's status as a leader in diagnostic accuracy. Through the implementation of advanced laboratory methodologies, the executive enhances the efficacy of products used in disease research. This leadership function drives the technical innovation necessary to solve critical challenges in the life sciences industry, ensuring that the company remains at the forefront of scientific advancement.